Insulin aspart
- Generic Name
- Insulin aspart
- Brand Names
- Fiasp, Novolog, Novolog Mix, Novomix, Novorapid, Novorapid Penfill, Ryzodeg, Truvelog Mix 30, Kirsty (previously Kixelle), NovoRapid, Insulin aspart Sanofi, NovoMix
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 116094-23-6
- Unique Ingredient Identifier
- D933668QVX
- Background
Insulin aspart is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin ...
- Indication
Insulin aspart is indicated to improve glycemic control in adults and children with diabetes mellitus.
- Associated Conditions
- Diabetes Mellitus, Diabetic Ketoacidosis, Gestational Diabetes Mellitus (GDM), Hyperglycemia during critical illness
- Associated Therapies
- -
A Trial Comparing Efficacy, Tolerability, and Safety of GZR101 Injection Once Daily (OD) and GZR33-70 Injection OD
- Conditions
- Interventions
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Gan and Lee Pharmaceuticals, USA
- Target Recruit Count
- 60
- Registration Number
- NCT06558708
- Locations
- 🇨🇳
Study Site 01, Tianjin, China
Role of ET-1, Physical Activity, and Sedentary Behavior in Microvascular Dysfunction Following GDM
- Conditions
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Anna Stanhewicz, PhD
- Target Recruit Count
- 40
- Registration Number
- NCT06547619
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
The Effect of Short-term Insulin Intensive Therapy Based on the Application of Insulin Pump and Real-time Dynamic Glucose Monitoring Technology on Reversing the Newly Diagnosed Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 210
- Registration Number
- NCT06127433
- Locations
- 🇨🇳
刘烈华, Guandong, China
Oxidative Stress in Microvascular Dysfunction Following Gestational Diabetes
- Conditions
- Interventions
- First Posted Date
- 2023-07-14
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Anna Stanhewicz, PhD
- Target Recruit Count
- 28
- Registration Number
- NCT05946785
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
Role of NADPH Oxidase in Microvascular Dysfunction Following GDM
- Conditions
- Interventions
- First Posted Date
- 2023-07-14
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Anna Stanhewicz, PhD
- Target Recruit Count
- 40
- Registration Number
- NCT05946798
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
Bioequivalence Study of INS062 and Pharmacokinetics and Pharmacokinetics Study of Single Injection of HR20014 in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2023-02-09
- Last Posted Date
- 2023-02-09
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT05719961
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers
- First Posted Date
- 2022-09-14
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Amphastar Pharmaceuticals, Inc.
- Target Recruit Count
- 69
- Registration Number
- NCT05539872
- Locations
- 🇺🇸
Amphastar Study Site, Chula Vista, California, United States
Pilot Study Evaluating Safety of ExOlin® in Patients With Poorly Controlled Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- Defymed
- Target Recruit Count
- 8
- Registration Number
- NCT05221359
- Locations
- 🇫🇷
Hôpitaux Universitaires de Strasbourg, Strasbourg, France
A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Target Recruit Count
- 12
- Registration Number
- NCT05199714
- Locations
- 🇨🇦
Research Institute of the McGill University Health Center, Montreal, Quebec, Canada
AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2022-09-13
- Lead Sponsor
- Arecor Limited
- Target Recruit Count
- 24
- Registration Number
- NCT05184868
- Locations
- 🇺🇸
ProSciento, Inc, Chula Vista, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.